There is 1 version of this bill. View text

Click the check-box to add or remove the section, click the text link to scroll to that section.
Titles Actions Overview All Actions Cosponsors Committees Related Bills Subjects Latest Summary All Summaries

Titles (2)

Short Titles

Short Titles - House of Representatives

Short Title(s) as Introduced

Faster Treatments and Cures for Eye Diseases Act

Official Titles

Official Titles - House of Representatives

Official Title as Introduced

To advance treatment and cures for blindness and other retinal conditions and to promote competitiveness in the United States through a pilot program to increase funding for translational research, and for other purposes.

Actions Overview (1)

Date Actions Overview
05/09/2019Introduced in House

All Actions (3)

Date All Actions
05/10/2019Referred to the Subcommittee on Health.
Action By: Committee on Energy and Commerce
05/09/2019Referred to the House Committee on Energy and Commerce.
Action By: House of Representatives
05/09/2019Introduced in House
Action By: House of Representatives

Cosponsors (21)

Committees (1)

Committees, subcommittees and links to reports associated with this bill are listed here, as well as the nature and date of committee activity and Congressional report number.

Committee / Subcommittee Date Activity Related Documents
House Energy and Commerce05/09/2019 Referred to
House Energy and Commerce Subcommittee on Health05/10/2019 Referred to

No related bill information was received for H.R.2620.

Latest Summary (1)

There is one summary for H.R.2620. View summaries

Shown Here:
Introduced in House (05/09/2019)

Faster Treatments and Cures for Eye Diseases Act

This bill requires the Department of Health and Human Services to establish a pilot program that provides for a partial federal guarantee of specified bonds, the sale of which shall finance promising translational vision-impairment research with private investment. The Government Accountability Office must study this program and consider whether similar programs should be established for other areas of biomedical research.